Quince Therapeutics Receives Nasdaq Non-Compliance Notices: What Investors Need to Know

Quince Therapeutics, Inc. (Nasdaq: QNCX) has disclosed critical developments that may significantly impact its share price and shareholder value. The company received two separate non-compliance notices from the Nasdaq Stock Market, both of which could have material consequences if not resolved in the coming months.

Key Points in the Report

• Minimum Bid Price Deficiency:
  • On March 16, 2026, Quince Therapeutics was notified by Nasdaq that its common stock closing bid price had been below the required minimum of \$1.00 per share for 30 consecutive business days.
  • To regain compliance, QNCX’s common stock must close at or above \$1.00 per share for at least 10 consecutive business days before the compliance deadline of September 14, 2026.
  • Nasdaq may, at its discretion, require the company to maintain the minimum bid price for more than 10 consecutive business days, but generally no more than 20.
  • If compliance is not regained by the deadline, the company may be eligible for an additional compliance period by transferring its listing to the Nasdaq Capital Market, subject to meeting certain other requirements and potentially effecting a reverse stock split.
• Market Value of Listed Securities (MVLS) Deficiency:
  • On March 17, 2026, Quince Therapeutics received a second notice from Nasdaq stating that its market value of listed securities had been below the \$50,000,000 minimum for the past 30 consecutive business days as required under Nasdaq Listing Rule 5450(b)(2)(A).
  • The company has until September 14, 2026, to regain compliance by ensuring its MVLS closes at or above \$50,000,000 for at least 10 consecutive business days (potentially up to 20 at Nasdaq’s discretion).
  • If compliance is not regained, the company will receive written notification that its securities are subject to delisting. The company can appeal this decision or may consider transferring to the Nasdaq Capital Market if eligibility criteria are met.

Important Information for Shareholders

• No Immediate Delisting: The receipt of these notices does not immediately affect the company’s listing. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the symbol “QNCX” while the company seeks to regain compliance.
• Potential Share Price Impact: These types of non-compliance notices are often viewed as negative by the market and may lead to increased volatility or downward pressure on the share price.
• Possible Actions: To address the deficiencies, Quince Therapeutics may consider a reverse stock split or other corporate actions to bring the share price and/or market value into compliance.
• Delisting Risk: Failure to regain compliance could result in a delisting of QNCX shares from the Nasdaq Global Select Market, which would likely have a material adverse effect on liquidity and share value. The company would have the option to appeal or transfer to the Nasdaq Capital Market, but there is no guarantee these steps would be successful.
• Company’s Response: Quince Therapeutics stated it intends to actively monitor its stock price and market value and is considering all available options for regaining compliance. However, there is no assurance the company will be able to do so within the required timeframe.

Why This News Is Price Sensitive

Non-compliance with Nasdaq’s listing standards is a significant event for any public company. It raises questions about the company’s long-term viability as a listed entity, can erode investor confidence, and may trigger forced selling by funds or investors who are restricted from holding non-compliant securities. The possibility of a reverse stock split or transfer to a lower-tier market also adds uncertainty to the company’s outlook.

Investors should closely monitor future announcements from Quince Therapeutics regarding their compliance efforts and be prepared for possible increased volatility in QNCX shares as the September 14, 2026 deadlines approach.

Company Details

• Company Name: Quince Therapeutics, Inc.
• Headquarters: 611 Gateway Blvd., Suite 273, South San Francisco, CA 94080
• CEO: Dirk Thye
• Ticker Symbol: QNCX
• Listing Exchange: Nasdaq Global Select Market

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are strongly encouraged to conduct their own due diligence and consult with qualified financial advisors before making any investment decisions. The situation described involves significant risks, including the potential for delisting and loss of liquidity, which could materially impact the value of Quince Therapeutics shares.

View Quince Therapeutics, Inc. Historical chart here